Idorsia Ltd
π¨πSwitzerland
Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT02223871
- Locations
- π¦πΊ
Q-Pharm Clinics, Herston, Queensland, Australia
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02186002
- Locations
- π«π·
OPTIMED Clinical Research, Gières, France
Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: ACT-389949 40 mgDrug: ACT-389949 200 mgDrug: ACT-389949 800 mgDrug: ACT-389949 (Group C1 dose to be selected)Drug: ACT-389949 (Group C2 dose to be selected)Drug: Placebo
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 65
- Registration Number
- NCT02099201
- Locations
- π¬π§
Celerion, Belfast, United Kingdom
Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: ACT-389949 1 mgDrug: ACT-389949 5 mgDrug: ACT-389949 20 mgDrug: ACT-389949 50 mgDrug: ACT-389949 100 mgDrug: ACT-389949 1000 mgDrug: ACT-389949 200 mgDrug: ACT-389949 500 mgDrug: Placebo
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 65
- Registration Number
- NCT02099071
- Locations
- π³π±
QPS Netherlands BV, Groningen, Netherlands
Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
- Interventions
- Drug: ACT-281959 prodrug formulation I (Groups C to G doses to be defined)Drug: 5 mg ACT-281959 prodrug formulation I (Group A)Drug: 20 mg ACT-281959 prodrug formulation I (Group B)Drug: Placebo (Groups A to F)Drug: ACT-281959 prodrug formulation II (Group G dose to be defined)
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT01954615
- Locations
- π«π·
Biotrial, Rennes, France
Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206
Phase 1
Completed
- Conditions
- SafetyTolerabilityPharmacodynamicsPharmacokinetics
- Interventions
- Drug: ACT-462206 5 mgDrug: ACT-462206 25 mgDrug: ACT-462206 100mgDrug: ACT-462206 200mgDrug: ACT-462206 1500mgDrug: ACT-462206 400mgDrug: ACT-462206 1000 mgDrug: Placebo
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT01954589
- Locations
- π³π±
Centre for Human Drug Research, Leiden, Netherlands
Clinical Study to Assess the Pharmacokinetics, Safety, and Tolerability of ACT-129968 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: ACT-129968 500 mg tabletDrug: ACT-129968 250 mg capsule
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT01877629
- Locations
- π©πͺ
PHAROS GmbH Clinical Research, Ulm, Germany
Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis
Phase 3
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 630
- Registration Number
- NCT01484119
- Locations
- πΊπΈ
Clinical Investigative Site 7903, New Braunfels, Texas, United States
πΊπΈClinical Investigative Site 7905, Austin, Texas, United States
πΊπΈClinical Investigative Site 7901, San Antonio, Texas, United States
Essential Hypertension
Phase 2
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2010-12-22
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 196
- Registration Number
- NCT01264692
- Locations
- π·πΈ
Clinical Investigative Site 3001, Belgrade, Serbia
π·πΈClinical Investigative Site 3004, Belgrade, Serbia
π·πΈClinical Investigative Site 3000, Niska Banja, Serbia
Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis
Phase 2
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 579
- Registration Number
- NCT01241214
- Locations
- πΊπΈ
Clinical Investigative Site 7902, San Antonio, Texas, United States
πΊπΈClinical Investigative Site 7901, San Antonio, Texas, United States
πΊπΈClinical Investigative Site 7906, San Antonio, Texas, United States
Β© Copyright 2025. All Rights Reserved by MedPath